Researchers at Lund University have developed a blood test capable of detecting signs of breast cancer recurrence long before recurrence becomes visible on imaging or causes symptoms.
An international research team led by the Medical University of Vienna has now identified a previously underestimated mechanism by which breast tumors evade the immune system.
Engineers at the University of California San Diego have created a soft, wearable ultrasound patch that can continuously monitor a fetus for hours at a time—and it can do so consistently even as the fetus and umbilical cord constantly move during pregnancy.
Researchers at Rice University, in collaboration with The University of Texas MD Anderson Cancer Center and clinical partners, have reported results from a first-in-human trial evaluating a novel cell-based platform for localized delivery of interleukin-2 (IL-2) in patients with advanced ovarian cancer.
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.
RNA therapy may calm abnormal brain activity of epilepsy in utero, before seizures emerge
https://med-techinsights.com/2026/04/22/new-tool-launches-to-support-women-through-post-loss-journey/
Earflo announced that it received FDA clearance for its non-invasive device designed to treat negative middle ear pressure in children.
LAGUNA HILLS, Calif., April 29, 2026 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the AidaBREAST® test.
Tandem Diabetes Care (Nasdaq:TNDM) today announced FDA clearance for its automated insulin delivery (AID) technology for use in pregnancy.